Scientists use AI to identify new aggressive prostate cancer type


  • Scientists used AI to find a new kind of aggressive prostate cancer, which could change how it’s treated.
  • They found two different types of prostate cancer by studying genetic data with AI.
  • This discovery may lead to more personalized treatment options for patients.

In a groundbreaking study published in Cell Genomics, scientists from the University of Oxford and the University of Manchester, UK, have utilized artificial intelligence (AI) to uncover a previously unknown form of aggressive prostate cancer. This discovery is poised to revolutionize the diagnosis and treatment of the disease, potentially saving thousands of lives in the future.

Unveiling two distinct subtypes

The research, led by Dan Woodcock and his team, challenges conventional understanding by revealing that prostate cancer comprises two distinct subtypes, termed serotypes. Through meticulous analysis of genetic data from thousands of prostate cancer samples across nine countries, the researchers identified these genotypes, shedding light on the intricate pathways through which the disease evolves.

AI-powered precision medicine

Central to the study is the integration of AI into the diagnostic process. By employing advanced neural networks, the scientists could discern the subtle genetic differences between the two cancer groups among 159 patients. This breakthrough, validated in independent datasets from Canada and Australia, signifies a shift towards personalized medicine in prostate cancer treatment.

The implications of this research extend beyond diagnosis, with profound implications for treatment strategies. Armed with a deeper understanding of how prostate tumors evolve, clinicians can now tailor treatments to individual patients, offering a more precise prognosis and enhancing overall treatment efficacy.

“Our research demonstrates that prostate tumors evolve along multiple pathways, leading to two distinct disease types,” explained lead researcher Dan Woodcock. “This understanding is pivotal as it allows us to classify tumors based on how the cancer evolves rather than solely on individual gene mutations or expression patterns.”

Collaborative efforts

This groundbreaking discovery results from a collaborative effort between various institutions, including The Institute of Cancer Research (ICR), The University of East Anglia, and Cancer Research UK (CRUK). 

The Pan Prostate Cancer Group, established by scientists at ICR and the University of East Anglia, facilitated the analysis of genetic data from diverse patient populations, laying the foundation for future advancements in prostate cancer research and treatment.

As oncology continues to embrace AI and genomic analysis, the potential for targeted therapies and personalized medicine is vast. By leveraging AI-driven insights, researchers and clinicians can unlock new avenues for understanding and treating cancer, offering hope to patients worldwide.

Disclaimer. The information provided is not trading advice. Cryptopolitan.com holds no liability for any investments made based on the information provided on this page. We strongly recommend independent research and/or consultation with a qualified professional before making any investment decisions.

Share link:

Benson Mawira

Benson is a blockchain reporter who has delved into industry news, on-chain analysis, non-fungible tokens (NFTs), Artificial Intelligence (AI), etc.His area of expertise is the cryptocurrency markets, fundamental and technical analysis.With his insightful coverage of everything in Financial Technologies, Benson has garnered a global readership.

Most read

Loading Most Read articles...

Stay on top of crypto news, get daily updates in your inbox

Related News

Subscribe to CryptoPolitan